A study has found over 95% of individuals in Sri Lanka developed antibodies against the Sinopharm vaccine.
The Allergy, Immunology and Cell Biology Unit of the Department of Immunology Molecular and Molecular Medicine at the University of Sri Jayewardenepura investigated immune responses to the Sinopharm vaccine and found that the vaccine induced antibody responses in over 95% of individuals, similar to levels seen following natural COVID-19 illness.
This vaccine was found very effective for the Delta variant as well.
The antibody responses to delta variant and neutralizing antibodies, were similar to levels seen following natural infection.
The study also found the antibody levels to delta and beta were similar to levels following natural infection although the antibody levels were lower for alpha.